Skip to main content
    S

    Seres Therapeutics Inc (MCRB)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.41
    +0.00 (+0.00%)

    Market Cap: $14.27M

    Last updated: Nov 17, 2026 at 4:10 PM ET

    Seres Therapeutics Inc (MCRB) Statistics

    Updated Nov 17, 2026. Figures from company filings and market prices; estimates from consensus analysts.

    Seres Therapeutics (MCRB) has a market cap of $14.27M. It kept -2209.55% of revenue as net income over the last 12 months. It holds $17.53M more cash than debt, 122.81% of its market cap.

    Total Valuation

    Market Cap$14.27M
    Latest price (Nov 17, 2026)$1.41

    Key Dates

    The next earnings report is expected on Mar 10, 2027, covering the quarter ending Dec 31, 2026.

    Next Earnings DateMar 10, 2027 (expected)
    Last Earnings DateNov 4, 2026
    Fiscal Year EndDecember

    Share Statistics

    The share count rose 2.84% in the quarter ended Sep 30, 2026 and grew 14.36% a year over 2 years.

    Shares Outstanding9.98M
    Shares Change (YoY)+13.97%
    Shares Change (QoQ)+2.84%
    Share Count Growth (2Y CAGR)+14.36%

    Valuation Ratios

    Sales and book value multiples are 6.6x and 0.7x. Its year-end P/S ranged from 5.2x to 670.5x from 2016 to 2023.

    P/S Ratio6.6x
    Forward P/S7.1x
    P/B Ratio0.7x

    Valuation history and multiples

    Price Statistics

    The stock is down 91.54% over 52 weeks and trades 49.46% below its 50-day average.

    Beta (1Y)1.43
    52-Week Change-91.54%
    1-Month Change-41.74%
    3-Month Change-69.87%
    6-Month Change-81.05%
    5-Year Change-98.54%
    10-Year Change-99.18%
    Total Return (1Y)-91.54%
    Total Return (3Y CAGR)-63.24%
    Total Return (5Y CAGR)-61.83%
    Return vs SPY (1Y)-105.85%
    Max Drawdown (1Y)-95.11%
    Max Drawdown (3Y)-95.51%
    Sharpe Ratio (1Y)-3.10
    Correlation with SPY (1Y)0.21
    50-Day Average$2.79
    200-Day Average$6.29
    52-Week Range$1.30 to $29.98
    RSI (14 Days)23.4
    Average Volume (20 Days)97.89K

    The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.

    Price chart

    Financial Position

    Current assets cover 1.65x current liabilities, and total debt is 0.00x shareholder equity.

    Current Ratio1.65x
    Quick Ratio1.65x
    Debt / Equity0.00x

    Returns and Efficiency

    Return on equity is -219.83% and return on assets is -71.26% over the last 12 months.

    Return on Equity (ROE)-219.83%
    Return on Assets (ROA)-71.26%
    ROA (5Y Average)-23.54%
    Asset Turnover0.02x
    Receivables Turnover9.30x

    Scores

    MCRB has an Altman Z-Score of -23.27, in the distress zone below 1.81, and a Piotroski F-Score of 4 of 9, in the average band of 3 to 7.

    Altman Z-Score-23.27
    Altman Z ZoneDistress
    Piotroski F-Score4 of 9
    Piotroski StrengthAverage

    Income Statement

    Revenue of $2.13M over the last 12 months is down 66.32% from the 12 months before.

    Revenue$2.13M
    Revenue Growth (YoY)-66.32%
    Gross Profit$2.13M
    Operating Income-$77.71M
    Pretax Income-$46.95M
    Net Income-$46.95M
    EBITDA-$45.16M
    Reported EPS (TTM)-$6.40

    Trailing 12 months through Sep 30, 2026.

    Full financial statements

    Balance Sheet

    Shareholder equity funds 32.42% of the $65.89M in total assets.

    Cash and Equivalents$17.53M
    Total Debt$0
    Net Cash$17.53M
    Net Cash Per Share$1.76
    Working Capital$13.53M
    Shareholder Equity$21.36M
    Book Value Per Share$2.14
    Total Assets$65.89M
    Total Liabilities$44.53M

    Balance sheet as of Sep 30, 2026.

    Full balance sheet

    Cash Flow

    Operating Cash Flow-$63.94M
    FCF Per Share-$6.37
    Depreciation and Amortization$2.89M

    Trailing 12 months through Sep 30, 2026.

    Full cash flow statement

    Margins

    The operating margin is -3656.89%.

    Gross Margin100.00%
    Operating Margin-3656.89%
    Pretax Margin-2209.55%
    Net Margin-2209.55%
    EBITDA Margin-2125.36%

    Dividends and Yields

    MCRB does not pay a dividend.

    Buyback Yield-107.04%
    Shareholder Yield-107.04%

    Stock Splits

    The last split was a 1-for-20 reverse split on Apr 22, 2025.

    Last Split DateApr 22, 2025
    Split TypeReverse split
    Split Ratio1:20

    Peer Position

    Against 6 similar companies, MCRB has the 5th highest P/S.

    P/S Ratio6.6x vs 11.4x median
    Revenue Growth (Trailing 4 Quarters, YoY)-66.32% vs -18.75% median

    Competitors compared

    Analyst Forecast

    Consensus estimates put revenue growth at -26.87% a year over the next 2 fiscal years.

    Revenue Growth Forecast (2Y CAGR)-26.87%

    Analyst estimates by year

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Frequently Asked Questions About MCRB

    What is MCRB's market cap?

    Seres Therapeutics has a market cap of $14.27M.

    How many shares of MCRB are outstanding?

    Seres Therapeutics has 9.98M shares outstanding. The count is up 13.97% from a year earlier.

    Does MCRB pay a dividend?

    No. Seres Therapeutics does not pay a dividend.

    How much debt does MCRB have?

    Seres Therapeutics has $0 of total debt and $17.53M of cash and equivalents, a net cash position of $17.53M.